1-5 of 5
Hannah Hunter, MB,FRCPath,MRCP
Close
Sort by
Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 701.
https://doi.org/10.1182/blood-2019-123442
Published: 2019
Journal Articles

Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT

Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Irma Khvedelidze, Hervé Finel, Karl Peggs, MBBChir, Ram K Malladi, FRCPath, Victoria Potter, Anna Tsoulkani, Elisabeth Vandenberghe, MD PhD, Yves Chalandon, MD PhD, Jürgen Finke, MD, Erik Marijt, MD, Sabine Furst, MD, Michel Schaap, MD PhD, Hannah Hunter, MB,FRCPath, MRCP, John A Snowden, MD PhD, Karan Wadehra, Sebastian Wittnebel, Dietrich W. Beelen, Nathalie Fegueux, Nicolaus Kroeger, MD, Peter Dreger, Silvia Montoto, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2070.
https://doi.org/10.1182/blood-2018-99-114072
Published: 2018
Journal Articles

Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study

Rohini Radia, MD FRCPath, Arun Alfred, Matthew P. Collin, MD PhD, Maria H Gilleece, MD FRCPath, MB, BSc, FRCP, James E Griffin, BSc (Hons), MBChB (Hons), PhD, Ann E. Hunter, MBBS, FRCP, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Harpreet Kaur, Nandita Khera, MD, Kavita Raj, MD PhD, Emma Das-Gupta, DM, FRCPath, MRCP, Fiona Louise Dignan, MD, Madan Jagasia, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 3408.
https://doi.org/10.1182/blood-2018-99-115376
Published: 2018
Journal Articles

Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)

Mark Cook, MBChB,PhD, Anesh Panchal, BSc, MSc, Kristian Brock, MSc, BSc, Grant McQuaker, MD, John A. Snowden, MD, Charles R Crawley, Hannah Hunter, MB,FRCPath,MRCP, James D Cavenagh, Mirjana Sirovica, BSc(Hons), MSc, Andrea Hodgkinson, BSc(Hons),PhD, Gordon Cook, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 3308.
https://doi.org/10.1182/blood.V130.Suppl_1.3308.3308
Published: 2017
Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 765.
https://doi.org/10.1182/blood.V122.21.765.765
Published: 2013